Inebilizumab for Autoimmune Hepatitis

(MERCURY Trial)

This trial aims to test inebilizumab, a new treatment for autoimmune hepatitis, to determine its safety and effectiveness in reducing disease activity and the need for certain medications. Autoimmune hepatitis occurs when the immune system attacks the liver, causing inflammation. Participants should have experienced this condition without adequate response to standard treatments for at least nine months or have faced significant side effects. The trial includes a comparison with a placebo (a substance with no therapeutic effect) to ensure that results are attributable to inebilizumab. As a Phase 3 trial, this study represents the final step before potential FDA approval, offering participants a chance to contribute to the development of a promising new treatment.

The trial requires that participants stay on stable doses of certain medications like azathioprine, 6-mercaptopurine, or mycophenolate for at least 12 weeks before starting the trial and throughout the treatment period. If you're on these medications, you won't need to stop them, but you should not be taking higher doses than specified.

Research has shown that inebilizumab is generally safe and well-tolerated. Since its approval in 2020, no reports have indicated liver problems caused by this medication, addressing a major safety concern for any drug. In other studies involving different conditions, about 9 to 10% of patients experienced mild infusion reactions during IV treatment. While these reactions warrant attention, they are not severe for most individuals. Overall, the available data suggests that inebilizumab's safety profile is promising.¹²³⁴⁵

Most treatments for autoimmune hepatitis involve using corticosteroids and immunosuppressants to reduce inflammation and suppress the immune system. But inebilizumab works differently by specifically targeting and depleting B cells, which are a type of immune cell involved in the disease. This targeted approach could mean fewer side effects compared to broad immunosuppressive therapies. Researchers are excited because targeting B cells directly may offer a more precise and effective way to manage autoimmune hepatitis.

Research shows that inebilizumab can help reduce symptoms of some autoimmune diseases. Studies have found it lowers the risk of flare-ups in immunoglobulin G4-related disease (IgG4-RD) and helps patients achieve remission. Specifically, those treated with inebilizumab experience fewer annual flare-ups compared to those on a placebo. In this trial, participants will receive either inebilizumab or a placebo as an IV infusion, alongside standard care, to evaluate its effects on autoimmune hepatitis (AIH). Although information on its effects on AIH remains limited, these findings suggest potential benefits for similar autoimmune conditions. Experts recognize its promise, given its success in reducing symptoms and promoting remission in related diseases.⁶⁷⁸⁹¹⁰